-
1
-
-
84866410479
-
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing
-
Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150:1107-1120.
-
(2012)
Cell.
, vol.150
, pp. 1107-1120
-
-
Imielinski, M.1
Berger, A.H.2
Hammerman, P.S.3
Hernandez, B.4
Pugh, T.J.5
Hodis, E.6
Cho, J.7
Suh, J.8
Capelletti, M.9
Sivachenko, A.10
Sougnez, C.11
Auclair, D.12
Lawrence, M.S.13
-
2
-
-
84862584058
-
Whole-genome analysis informs breast cancer response to aromatase inhibition
-
Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486:353-360.
-
(2012)
Nature.
, vol.486
, pp. 353-360
-
-
Ellis, M.J.1
Ding, L.2
Shen, D.3
Luo, J.4
Suman, V.J.5
Wallis, J.W.6
Van Tine, B.A.7
Hoog, J.8
Goiffon, R.J.9
Goldstein, T.C.10
Ng, S.11
Lin, L.12
Crowder, R.13
-
3
-
-
84885074034
-
The somatic genomic landscape of glioblastoma
-
Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462-477.
-
(2013)
Cell.
, vol.155
, pp. 462-477
-
-
Brennan, C.W.1
Verhaak, R.G.2
McKenna, A.3
Campos, B.4
Noushmehr, H.5
Salama, S.R.6
Zheng, S.7
Chakravarty, D.8
Sanborn, J.Z.9
Berman, S.H.10
Beroukhim, R.11
Bernard, B.12
Wu, C.J.13
-
4
-
-
84875490185
-
Cancer genome landscapes
-
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546-1558.
-
(2013)
Science.
, vol.339
, pp. 1546-1558
-
-
Vogelstein, B.1
Papadopoulos, N.2
Velculescu, V.E.3
Zhou, S.4
Diaz, L.A.5
Kinzler, K.W.6
-
6
-
-
84907942181
-
Development of synthetic lethality anticancer therapeutics
-
Fang B. Development of synthetic lethality anticancer therapeutics. J Med Chem. 2014;57:7859-7873.
-
(2014)
J Med Chem.
, vol.57
, pp. 7859-7873
-
-
Fang, B.1
-
7
-
-
54549094903
-
Somatic mutations affect key pathways in lung adenocarcinoma
-
Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455:1069-1075.
-
(2008)
Nature.
, vol.455
, pp. 1069-1075
-
-
Ding, L.1
Getz, G.2
Wheeler, D.A.3
Mardis, E.R.4
McLellan, M.D.5
Cibulskis, K.6
Sougnez, C.7
Greulich, H.8
Muzny, D.M.9
Morgan, M.B.10
Fulton, L.11
Fulton, R.S.12
Zhang, Q.13
-
8
-
-
84866434919
-
Genomic landscape of nonsmall cell lung cancer in smokers and never-smokers
-
Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R, Fulton L, Wallis J, Chen K, Walker J, McDonald S, et al. Genomic landscape of nonsmall cell lung cancer in smokers and never-smokers. Cell. 2012;150:1121-1134.
-
(2012)
Cell.
, vol.150
, pp. 1121-1134
-
-
Govindan, R.1
Ding, L.2
Griffith, M.3
Subramanian, J.4
Dees, N.D.5
Kanchi, K.L.6
Maher, C.A.7
Fulton, R.8
Fulton, L.9
Wallis, J.10
Chen, K.11
Walker, J.12
McDonald, S.13
-
9
-
-
84867557923
-
A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer
-
Soda M, Isobe K, Inoue A, Maemondo M, Oizumi S, Fujita Y, Gemma A, Yamashita Y, Ueno T, Takeuchi K, Choi YL, Miyazawa H, Tanaka T, et al. A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin Cancer Res. 2012;18:5682-5689.
-
(2012)
Clin Cancer Res.
, vol.18
, pp. 5682-5689
-
-
Soda, M.1
Isobe, K.2
Inoue, A.3
Maemondo, M.4
Oizumi, S.5
Fujita, Y.6
Gemma, A.7
Yamashita, Y.8
Ueno, T.9
Takeuchi, K.10
Choi, Y.L.11
Miyazawa, H.12
Tanaka, T.13
-
10
-
-
27544503230
-
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
-
Thatcher N, Chang A, Parikh P, Rodrigues PJ, Ciuleanu T, von PJ, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527-1537.
-
(2005)
Lancet.
, vol.366
, pp. 1527-1537
-
-
Thatcher, N.1
Chang, A.2
Parikh, P.3
Rodrigues, P.J.4
Ciuleanu, T.5
von, P.J.6
Thongprasert, S.7
Tan, E.H.8
Pemberton, K.9
Archer, V.10
Carroll, K.11
-
11
-
-
57149089886
-
EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan
-
Takano T, Fukui T, Ohe Y, Tsuta K, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Furuta K, Tamura T. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol. 2008;26:5589-5595.
-
(2008)
J Clin Oncol.
, vol.26
, pp. 5589-5595
-
-
Takano, T.1
Fukui, T.2
Ohe, Y.3
Tsuta, K.4
Yamamoto, S.5
Nokihara, H.6
Yamamoto, N.7
Sekine, I.8
Kunitoh, H.9
Furuta, K.10
Tamura, T.11
-
12
-
-
0032850677
-
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
-
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648.
-
(1999)
J Clin Oncol.
, vol.17
, pp. 2639-2648
-
-
Cobleigh, M.A.1
Vogel, C.L.2
Tripathy, D.3
Robert, N.J.4
Scholl, S.5
Fehrenbacher, L.6
Wolter, J.M.7
Paton, V.8
Shak, S.9
Lieberman, G.10
Slamon, D.J.11
-
13
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
-
(2001)
N Engl J Med.
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
Fleming, T.7
Eiermann, W.8
Wolter, J.9
Pegram, M.10
Baselga, J.11
Norton, L.12
-
14
-
-
4444344330
-
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
-
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306-13311.
-
(2004)
Proc Natl Acad Sci USA.
, vol.101
, pp. 13306-13311
-
-
Pao, W.1
Miller, V.2
Zakowski, M.3
Doherty, J.4
Politi, K.5
Sarkaria, I.6
Singh, B.7
Heelan, R.8
Rusch, V.9
Fulton, L.10
Mardis, E.11
Kupfer, D.12
Wilson, R.13
-
15
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
-
(2004)
N Engl J Med.
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
Gurubhagavatula, S.4
Okimoto, R.A.5
Brannigan, B.W.6
Harris, P.L.7
Haserlat, S.M.8
Supko, J.G.9
Haluska, F.G.10
Louis, D.N.11
Christiani, D.C.12
Settleman, J.13
-
16
-
-
2342624080
-
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
-
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500.
-
(2004)
Science.
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
Janne, P.A.2
Lee, J.C.3
Tracy, S.4
Greulich, H.5
Gabriel, S.6
Herman, P.7
Kaye, F.J.8
Lindeman, N.9
Boggon, T.J.10
Naoki, K.11
Sasaki, H.12
Fujii, Y.13
-
17
-
-
34248140107
-
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial
-
Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De RF, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007;25:1545-1552.
-
(2007)
J Clin Oncol.
, vol.25
, pp. 1545-1552
-
-
Gatzemeier, U.1
Pluzanska, A.2
Szczesna, A.3
Kaukel, E.4
Roubec, J.5
De, R.F.6
Milanowski, J.7
Karnicka-Mlodkowski, H.8
Pesek, M.9
Serwatowski, P.10
Ramlau, R.11
Janaskova, T.12
Vansteenkiste, J.13
-
18
-
-
24944440830
-
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced nonsmall-cell lung cancer
-
Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced nonsmall-cell lung cancer. J Clin Oncol. 2005;23:5892-5899.
-
(2005)
J Clin Oncol.
, vol.23
, pp. 5892-5899
-
-
Herbst, R.S.1
Prager, D.2
Hermann, R.3
Fehrenbacher, L.4
Johnson, B.E.5
Sandler, A.6
Kris, M.G.7
Tran, H.T.8
Klein, P.9
Li, X.10
Ramies, D.11
Johnson, D.H.12
Miller, V.A.13
-
19
-
-
54749152429
-
Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota
-
Guo W, Wu S, Liu J, Fang B. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res. 2008;68:7403-7408.
-
(2008)
Cancer Res.
, vol.68
, pp. 7403-7408
-
-
Guo, W.1
Wu, S.2
Liu, J.3
Fang, B.4
-
20
-
-
83155191802
-
Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition
-
Guo W, Wu S, Wang L, Wei X, Liu X, Wang J, Lu Z, Hollingshead M, Fang B. Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition. PLoS ONE. 2011;6:e28487.
-
(2011)
PLoS ONE.
, vol.6
-
-
Guo, W.1
Wu, S.2
Wang, L.3
Wei, X.4
Liu, X.5
Wang, J.6
Lu, Z.7
Hollingshead, M.8
Fang, B.9
-
21
-
-
67650550815
-
Inhibiting JNK dephosphorylation and induction of apoptosis by novel anticancer agent NSC-741909 in cancer cells
-
Wei X, Guo W, Wu S, Wang L, Lu Y, Xu B, Liu J, Fang B. Inhibiting JNK dephosphorylation and induction of apoptosis by novel anticancer agent NSC-741909 in cancer cells. J Biol Chem. 2009;284:16948-16955.
-
(2009)
J Biol Chem.
, vol.284
, pp. 16948-16955
-
-
Wei, X.1
Guo, W.2
Wu, S.3
Wang, L.4
Lu, Y.5
Xu, B.6
Liu, J.7
Fang, B.8
-
22
-
-
79955415299
-
Analogues and derivatives of oncrasin-1, a novel inhibitor of the C-terminal domain of RNA polymerase II and their antitumor activities
-
Wu S, Wang L, Guo W, Liu X, Liu J, Wei X, Fang B. Analogues and derivatives of oncrasin-1, a novel inhibitor of the C-terminal domain of RNA polymerase II and their antitumor activities. J Med Chem. 2011;54:2668-2679.
-
(2011)
J Med Chem.
, vol.54
, pp. 2668-2679
-
-
Wu, S.1
Wang, L.2
Guo, W.3
Liu, X.4
Liu, J.5
Wei, X.6
Fang, B.7
-
23
-
-
60849135119
-
Interruption of RNA processing machinery by a small compound 1-[(4-chlorophenyl) methyl]-1H-indole-3-carboxaldehyde (oncrasin-1)
-
Guo W, Wu S, Wang L, Wang R, Wei L, Liu J, Fang B. Interruption of RNA processing machinery by a small compound 1-[(4-chlorophenyl) methyl]-1H-indole-3-carboxaldehyde (oncrasin-1). Mol Cancer Ther. 2009;8:441-448.
-
(2009)
Mol Cancer Ther.
, vol.8
, pp. 441-448
-
-
Guo, W.1
Wu, S.2
Wang, L.3
Wang, R.4
Wei, L.5
Liu, J.6
Fang, B.7
-
24
-
-
77950822385
-
Oxidative stress in NSC-741909-induced apoptosis of cancer cells
-
Wei X, Guo W, Wu S, Wang L, Huang P, Liu J, Fang B. Oxidative stress in NSC-741909-induced apoptosis of cancer cells. J Transl Med. 2010;8:37.
-
(2010)
J Transl Med.
, vol.8
, pp. 37
-
-
Wei, X.1
Guo, W.2
Wu, S.3
Wang, L.4
Huang, P.5
Liu, J.6
Fang, B.7
-
25
-
-
84862796550
-
Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells
-
Liu X, Guo W, Wu S, Wang L, Wang J, Dai B, Kim ES, Heymach JV, Wang M, Girard L, Minna J, Roth JA, Swisher SG, et al. Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells. Biochem Pharmacol. 2012;83:1456-1464.
-
(2012)
Biochem Pharmacol.
, vol.83
, pp. 1456-1464
-
-
Liu, X.1
Guo, W.2
Wu, S.3
Wang, L.4
Wang, J.5
Dai, B.6
Kim, E.S.7
Heymach, J.V.8
Wang, M.9
Girard, L.10
Minna, J.11
Roth, J.A.12
Swisher, S.G.13
-
26
-
-
84863953497
-
Intestinal carcinogenesis of two food processing contaminants, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 5-hydroxymethylfurfural, in transgenic FVB min mice expressing human sulfotransferases
-
Svendsen C, Meinl W, Glatt H, Alexander J, Knutsen HK, Hjertholm H, Rasmussen T, Husoy T. Intestinal carcinogenesis of two food processing contaminants, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 5-hydroxymethylfurfural, in transgenic FVB min mice expressing human sulfotransferases. Mol Carcinog. 2012;51:984-992.
-
(2012)
Mol Carcinog.
, vol.51
, pp. 984-992
-
-
Svendsen, C.1
Meinl, W.2
Glatt, H.3
Alexander, J.4
Knutsen, H.K.5
Hjertholm, H.6
Rasmussen, T.7
Husoy, T.8
-
27
-
-
84869109930
-
Possible involvement of sulfotransferase 1A1 in estragole-induced DNA modification and carcinogenesis in the livers of female mice
-
Suzuki Y, Umemura T, Ishii Y, Hibi D, Inoue T, Jin M, Sakai H, Kodama Y, Nohmi T, Yanai T, Nishikawa A, Ogawa K. Possible involvement of sulfotransferase 1A1 in estragole-induced DNA modification and carcinogenesis in the livers of female mice. Mutat Res. 2012;749:23-28.
-
(2012)
Mutat Res.
, vol.749
, pp. 23-28
-
-
Suzuki, Y.1
Umemura, T.2
Ishii, Y.3
Hibi, D.4
Inoue, T.5
Jin, M.6
Sakai, H.7
Kodama, Y.8
Nohmi, T.9
Yanai, T.10
Nishikawa, A.11
Ogawa, K.12
-
28
-
-
0037470234
-
Structure of a human carcinogen-converting enzyme, SULT1A1 Structural and kinetic implications of substrate inhibition.
-
Gamage NU, Duggleby RG, Barnett AC, Tresillian M, Latham CF, Liyou NE, McManus ME, Martin JL. Structure of a human carcinogen-converting enzyme, SULT1A1. Structural and kinetic implications of substrate inhibition. J Biol Chem. 2003;278:7655-7662.
-
(2003)
J Biol Chem.
, vol.278
, pp. 7655-7662
-
-
Gamage, N.U.1
Duggleby, R.G.2
Barnett, A.C.3
Tresillian, M.4
Latham, C.F.5
Liyou, N.E.6
McManus, M.E.7
Martin, J.L.8
-
29
-
-
0036850037
-
Metabolic activation of the environmental contaminant 3-nitrobenzanthrone by human acetyltransferases and sulfotransferase
-
Arlt VM, Glatt H, Muckel E, Pabel U, Sorg BL, Schmeiser HH, Phillips DH. Metabolic activation of the environmental contaminant 3-nitrobenzanthrone by human acetyltransferases and sulfotransferase. Carcinogenesis. 2002;23:1937-1945.
-
(2002)
Carcinogenesis.
, vol.23
, pp. 1937-1945
-
-
Arlt, V.M.1
Glatt, H.2
Muckel, E.3
Pabel, U.4
Sorg, B.L.5
Schmeiser, H.H.6
Phillips, D.H.7
-
30
-
-
0026773537
-
Activation of a beta-hydroxyalkylnitrosamine to alkylating agents: evidence for the involvement of a sulfotransferase
-
Kroeger-Koepke MB, Koepke SR, Hernandez L, Michejda CJ. Activation of a beta-hydroxyalkylnitrosamine to alkylating agents: evidence for the involvement of a sulfotransferase. Cancer Res. 1992;52:3300-3305.
-
(1992)
Cancer Res.
, vol.52
, pp. 3300-3305
-
-
Kroeger-Koepke, M.B.1
Koepke, S.R.2
Hernandez, L.3
Michejda, C.J.4
-
31
-
-
84894561504
-
Formation of hepatic DNA adducts by methyleugenol in mouse models: drastic decrease by Sult1a1 knockout and strong increase by transgenic human SULT1A1/2
-
Herrmann K, Engst W, Meinl W, Florian S, Cartus AT, Schrenk D, Appel KE, Nolden T, Himmelbauer H, Glatt H. Formation of hepatic DNA adducts by methyleugenol in mouse models: drastic decrease by Sult1a1 knockout and strong increase by transgenic human SULT1A1/2. Carcinogenesis. 2014;35:935-941.
-
(2014)
Carcinogenesis.
, vol.35
, pp. 935-941
-
-
Herrmann, K.1
Engst, W.2
Meinl, W.3
Florian, S.4
Cartus, A.T.5
Schrenk, D.6
Appel, K.E.7
Nolden, T.8
Himmelbauer, H.9
Glatt, H.10
-
32
-
-
0031593138
-
The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines
-
Malich G, Markovic B, Winder C. The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology. 1997;124:179-192.
-
(1997)
Toxicology.
, vol.124
, pp. 179-192
-
-
Malich, G.1
Markovic, B.2
Winder, C.3
-
33
-
-
33144464115
-
Human sulfotransferases and their role in chemical metabolism
-
Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, Martin JL, McManus ME. Human sulfotransferases and their role in chemical metabolism. Toxicol Sci. 2006;90:5-22.
-
(2006)
Toxicol Sci.
, vol.90
, pp. 5-22
-
-
Gamage, N.1
Barnett, A.2
Hempel, N.3
Duggleby, R.G.4
Windmill, K.F.5
Martin, J.L.6
McManus, M.E.7
-
34
-
-
0029916538
-
Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines
-
Falany JL, Falany CN. Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines. Cancer Res. 1996;56:1551-1555.
-
(1996)
Cancer Res.
, vol.56
, pp. 1551-1555
-
-
Falany, J.L.1
Falany, C.N.2
-
35
-
-
77954630330
-
Expression of sulfotransferase isoform 1A1 (SULT1A1) in breast cancer cells significantly increases 4-hydroxytamoxifen-induced apoptosis
-
Mercer KE, Apostolov EO, da Costa GG, Yu X, Lang P, Roberts DW, Davis W, Basnakian AG, Kadlubar FF, Kadlubar SA. Expression of sulfotransferase isoform 1A1 (SULT1A1) in breast cancer cells significantly increases 4-hydroxytamoxifen-induced apoptosis. Int J Mol Epidemiol Genet. 2010;1:92-103.
-
(2010)
Int J Mol Epidemiol Genet.
, vol.1
, pp. 92-103
-
-
Mercer, K.E.1
Apostolov, E.O.2
da Costa, G.G.3
Yu, X.4
Lang, P.5
Roberts, D.W.6
Davis, W.7
Basnakian, A.G.8
Kadlubar, F.F.9
Kadlubar, S.A.10
-
36
-
-
75649093034
-
Activity of sulfotransferase 1A1 is dramatically upregulated in patients with hepatocellular carcinoma secondary to chronic hepatitis B virus infection
-
Wang XR, Qu ZQ, Li XD, Liu HL, He P, Fang BX, Xiao J, Huang W, Wu MC. Activity of sulfotransferase 1A1 is dramatically upregulated in patients with hepatocellular carcinoma secondary to chronic hepatitis B virus infection. Cancer Sci. 2010;101:412-415.
-
(2010)
Cancer Sci.
, vol.101
, pp. 412-415
-
-
Wang, X.R.1
Qu, Z.Q.2
Li, X.D.3
Liu, H.L.4
He, P.5
Fang, B.X.6
Xiao, J.7
Huang, W.8
Wu, M.C.9
-
37
-
-
0034967098
-
Sulfation of thyroid hormone and dopamine during human development: ontogeny of phenol sulfotransferases and arylsulfatase in liver, lung, and brain
-
Richard K, Hume R, Kaptein E, Stanley EL, Visser TJ, Coughtrie MW. Sulfation of thyroid hormone and dopamine during human development: ontogeny of phenol sulfotransferases and arylsulfatase in liver, lung, and brain. J Clin Endocrinol Metab. 2001;86:2734-2742.
-
(2001)
J Clin Endocrinol Metab.
, vol.86
, pp. 2734-2742
-
-
Richard, K.1
Hume, R.2
Kaptein, E.3
Stanley, E.L.4
Visser, T.J.5
Coughtrie, M.W.6
-
38
-
-
70350319524
-
Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT "pie"
-
Riches Z, Stanley EL, Bloomer JC, Coughtrie MW. Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT "pie". Drug Metab Dispos. 2009;37:2255-2261.
-
(2009)
Drug Metab Dispos.
, vol.37
, pp. 2255-2261
-
-
Riches, Z.1
Stanley, E.L.2
Bloomer, J.C.3
Coughtrie, M.W.4
-
39
-
-
63849173713
-
Expression and localization of cytosolic sulfotransferase (SULT) 1A1 and SULT1A3 in normal human brain
-
Salman ED, Kadlubar SA, Falany CN. Expression and localization of cytosolic sulfotransferase (SULT) 1A1 and SULT1A3 in normal human brain. Drug Metab Dispos. 2009;37:706-709.
-
(2009)
Drug Metab Dispos.
, vol.37
, pp. 706-709
-
-
Salman, E.D.1
Kadlubar, S.A.2
Falany, C.N.3
-
40
-
-
78651103298
-
The association of SULT1A1 codon 213 polymorphism and breast cancer susceptibility: metaanalysis from 16 studies involving 23,445 subjects
-
Sun Y, Zang Z, Xu X, Zhang Z, Zhong L, Zan W, Zhao Y, Sun L. The association of SULT1A1 codon 213 polymorphism and breast cancer susceptibility: metaanalysis from 16 studies involving 23,445 subjects. Br Cancer Res Treat. 2011;125:215-219.
-
(2011)
Br Cancer Res Treat.
, vol.125
, pp. 215-219
-
-
Sun, Y.1
Zang, Z.2
Xu, X.3
Zhang, Z.4
Zhong, L.5
Zan, W.6
Zhao, Y.7
Sun, L.8
-
41
-
-
77954667307
-
Association of sulfotransferase SULT1A1 with breast cancer risk: a meta-analysis of case-control studies with subgroups of ethnic and menopausal statue
-
Jiang Y, Zhou L, Yan T, Shen Z, Shao Z, Lu J. Association of sulfotransferase SULT1A1 with breast cancer risk: a meta-analysis of case-control studies with subgroups of ethnic and menopausal statue. J Exp Clin Cancer Res. 2010;29:101.
-
(2010)
J Exp Clin Cancer Res.
, vol.29
, pp. 101
-
-
Jiang, Y.1
Zhou, L.2
Yan, T.3
Shen, Z.4
Shao, Z.5
Lu, J.6
-
42
-
-
77953540965
-
SULT1A1 R213H polymorphism and breast cancer risk: a meta-analysis based on 8,454 cases and 11,800 controls
-
Wang Z, Fu Y, Tang C, Lu S, Chu WM. SULT1A1 R213H polymorphism and breast cancer risk: a meta-analysis based on 8,454 cases and 11,800 controls. Br Cancer Res Treat. 2010;122:193-198.
-
(2010)
Br Cancer Res Treat.
, vol.122
, pp. 193-198
-
-
Wang, Z.1
Fu, Y.2
Tang, C.3
Lu, S.4
Chu, W.M.5
-
43
-
-
83655198352
-
Multiple analytical approaches reveal distinct geneenvironment interactions in smokers and non smokers in lung cancer
-
Ihsan R, Chauhan PS, Mishra AK, Yadav DS, Kaushal M, Sharma JD, Zomawia E, Verma Y, Kapur S, Saxena S. Multiple analytical approaches reveal distinct geneenvironment interactions in smokers and non smokers in lung cancer. PLoS ONE. 2011;6:e29431.
-
(2011)
PLoS ONE.
, vol.6
-
-
Ihsan, R.1
Chauhan, P.S.2
Mishra, A.K.3
Yadav, D.S.4
Kaushal, M.5
Sharma, J.D.6
Zomawia, E.7
Verma, Y.8
Kapur, S.9
Saxena, S.10
-
44
-
-
80055091500
-
Association between cancer risk and drugmetabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan
-
Tamaki Y, Arai T, Sugimura H, Sasaki T, Honda M, Muroi Y, Matsubara Y, Kanno S, Ishikawa M, Hirasawa N, Hiratsuka M. Association between cancer risk and drugmetabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan. Drug Metab Pharmacokinet. 2011;26:516-522.
-
(2011)
Drug Metab Pharmacokinet.
, vol.26
, pp. 516-522
-
-
Tamaki, Y.1
Arai, T.2
Sugimura, H.3
Sasaki, T.4
Honda, M.5
Muroi, Y.6
Matsubara, Y.7
Kanno, S.8
Ishikawa, M.9
Hirasawa, N.10
Hiratsuka, M.11
-
45
-
-
79958715494
-
Lack of association of SULT1A1 R213H polymorphism with colorectal cancer: a meta-analysis
-
Zhang C, Li JP, Lv GQ, Yu XM, Gu YL, Zhou P. Lack of association of SULT1A1 R213H polymorphism with colorectal cancer: a meta-analysis. PLoS ONE. 2011;6:e19127.
-
(2011)
PLoS ONE.
, vol.6
-
-
Zhang, C.1
Li, J.P.2
Lv, G.Q.3
Yu, X.M.4
Gu, Y.L.5
Zhou, P.6
-
46
-
-
33845403056
-
SULT1A1 genotype and susceptibility to colorectal cancer
-
Lilla C, Risch A, Verla-Tebit E, Hoffmeister M, Brenner H, Chang-Claude J. SULT1A1 genotype and susceptibility to colorectal cancer. Int J Cancer. 2007;120:201-206.
-
(2007)
Int J Cancer.
, vol.120
, pp. 201-206
-
-
Lilla, C.1
Risch, A.2
Verla-Tebit, E.3
Hoffmeister, M.4
Brenner, H.5
Chang-Claude, J.6
-
47
-
-
0344827259
-
Sulfotransferase 1A1 (SULT1A1) polymorphism and bladder cancer risk: a case-control study
-
Zheng L, Wang Y, Schabath MB, Grossman HB, Wu X. Sulfotransferase 1A1 (SULT1A1) polymorphism and bladder cancer risk: a case-control study. Cancer Lett. 2003;202:61-69.
-
(2003)
Cancer Lett.
, vol.202
, pp. 61-69
-
-
Zheng, L.1
Wang, Y.2
Schabath, M.B.3
Grossman, H.B.4
Wu, X.5
-
48
-
-
35848971201
-
Sulfotransferase 1A1 (SULT1A1) polymorphism and susceptibility to primary brain tumors
-
Bardakci F, Arslan S, Bardakci S, Binatli AO, Budak M. Sulfotransferase 1A1 (SULT1A1) polymorphism and susceptibility to primary brain tumors. J Cancer Res Clin Oncol. 2008;134:109-114.
-
(2008)
J Cancer Res Clin Oncol.
, vol.134
, pp. 109-114
-
-
Bardakci, F.1
Arslan, S.2
Bardakci, S.3
Binatli, A.O.4
Budak, M.5
-
49
-
-
0037032497
-
Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy
-
Nowell S, Sweeney C, Winters M, Stone A, Lang NP, Hutchins LF, Kadlubar FF, Ambrosone CB. Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst. 2002;94:1635-1640.
-
(2002)
J Natl Cancer Inst.
, vol.94
, pp. 1635-1640
-
-
Nowell, S.1
Sweeney, C.2
Winters, M.3
Stone, A.4
Lang, N.P.5
Hutchins, L.F.6
Kadlubar, F.F.7
Ambrosone, C.B.8
-
50
-
-
33747610305
-
Activation of aminoflavone (NSC 686288) by a sulfotransferase is required for the antiproliferative effect of the drug and for induction of histone gamma-H2AX
-
Meng LH, Shankavaram U, Chen C, Agama K, Fu HQ, Gonzalez FJ, Weinstein J, Pommier Y. Activation of aminoflavone (NSC 686288) by a sulfotransferase is required for the antiproliferative effect of the drug and for induction of histone gamma-H2AX. Cancer Res. 2006;66:9656-9664.
-
(2006)
Cancer Res.
, vol.66
, pp. 9656-9664
-
-
Meng, L.H.1
Shankavaram, U.2
Chen, C.3
Agama, K.4
Fu, H.Q.5
Gonzalez, F.J.6
Weinstein, J.7
Pommier, Y.8
-
51
-
-
79959712087
-
Ras/ Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health
-
Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Basecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, et al. Ras/ Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget. 2011;2:135-164.
-
(2011)
Oncotarget.
, vol.2
, pp. 135-164
-
-
Chappell, W.H.1
Steelman, L.S.2
Long, J.M.3
Kempf, R.C.4
Abrams, S.L.5
Franklin, R.A.6
Basecke, J.7
Stivala, F.8
Donia, M.9
Fagone, P.10
Malaponte, G.11
Mazzarino, M.C.12
Nicoletti, F.13
-
52
-
-
79960052850
-
Ras in cancer and developmental diseases
-
Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer. 2011;2:344-358.
-
(2011)
Genes Cancer.
, vol.2
, pp. 344-358
-
-
Fernandez-Medarde, A.1
Santos, E.2
-
53
-
-
65649108558
-
A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival
-
Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, Settleman J. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell. 2009;15:489-500.
-
(2009)
Cancer Cell.
, vol.15
, pp. 489-500
-
-
Singh, A.1
Greninger, P.2
Rhodes, D.3
Koopman, L.4
Violette, S.5
Bardeesy, N.6
Settleman, J.7
-
54
-
-
70449091786
-
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
-
Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Frohling S, Chan EM, Sos ML, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108-112.
-
(2009)
Nature.
, vol.462
, pp. 108-112
-
-
Barbie, D.A.1
Tamayo, P.2
Boehm, J.S.3
Kim, S.Y.4
Moody, S.E.5
Dunn, I.F.6
Schinzel, A.C.7
Sandy, P.8
Meylan, E.9
Scholl, C.10
Frohling, S.11
Chan, E.M.12
Sos, M.L.13
-
55
-
-
84905009543
-
Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells
-
Brunelli L, Caiola E, Marabese M, Broggini M, Pastorelli R. Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells. Oncotarget. 2014;5:4722-4731.
-
(2014)
Oncotarget.
, vol.5
, pp. 4722-4731
-
-
Brunelli, L.1
Caiola, E.2
Marabese, M.3
Broggini, M.4
Pastorelli, R.5
-
56
-
-
18344371925
-
Tobacco smokeinduced lung tumorigenesis in mutant A/J mice with alterations in K-ras, p53, or Ink4a/Arf
-
Wang Y, Zhang Z, Lubet R, You M. Tobacco smokeinduced lung tumorigenesis in mutant A/J mice with alterations in K-ras, p53, or Ink4a/Arf. Oncogene. 2005;24:3042-3049.
-
(2005)
Oncogene.
, vol.24
, pp. 3042-3049
-
-
Wang, Y.1
Zhang, Z.2
Lubet, R.3
You, M.4
-
57
-
-
0035883542
-
Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung
-
Ahrendt SA, Decker PA, Alawi EA, Zhu Yr YR, Sanchez-Cespedes M, Yang SC, Haasler GB, Kajdacsy-Balla A, Demeure MJ, Sidransky D. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer. 2001;92:1525-1530.
-
(2001)
Cancer.
, vol.92
, pp. 1525-1530
-
-
Ahrendt, S.A.1
Decker, P.A.2
Alawi, E.A.3
Zhu Yr, Y.R.4
Sanchez-Cespedes, M.5
Yang, S.C.6
Haasler, G.B.7
Kajdacsy-Balla, A.8
Demeure, M.J.9
Sidransky, D.10
-
58
-
-
0025851146
-
Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung
-
Slebos RJ, Hruban RH, Dalesio O, Mooi WJ, Offerhaus GJ, Rodenhuis S. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst. 1991;83:1024-1027.
-
(1991)
J Natl Cancer Inst.
, vol.83
, pp. 1024-1027
-
-
Slebos, R.J.1
Hruban, R.H.2
Dalesio, O.3
Mooi, W.J.4
Offerhaus, G.J.5
Rodenhuis, S.6
-
59
-
-
77958603331
-
Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim
-
Meng J, Fang B, Liao Y, Chresta CM, Smith PD, Roth JA. Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim. PLoS ONE. 2010;5:e13026.
-
(2010)
PLoS ONE.
, vol.5
-
-
Meng, J.1
Fang, B.2
Liao, Y.3
Chresta, C.M.4
Smith, P.D.5
Roth, J.A.6
-
60
-
-
0038156106
-
Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values
-
Pounds S, Morris SW. Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values. Bioinformatics. 2003;19:1236-1242.
-
(2003)
Bioinformatics.
, vol.19
, pp. 1236-1242
-
-
Pounds, S.1
Morris, S.W.2
|